ArticleMMWR. Morbidity and mortality weekly report2020
Vital Signs: Prescription Opioid Pain Reliever Use During Pregnancy - 34 U.S. Jurisdictions, 2019.
Article in MMWR. Morbidity and mortality weekly report, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Opioid exposure during pregnancy and the risk of congenital malformation: a meta-analysis of cohort studies.BMC pregnancy and childbirth · 2022Pooled it
- Physiologically based pharmacokinetic modeling of long-acting extended-release naltrexone in pregnant women with opioid use disorder.CPT: pharmacometrics & systems pharmacology · 2024Trial
- Maternal opioid prescriptions and subsequent risk of hospital admission in offspring in South Korea: A nationwide birth cohort study.PLoS medicine · 2026Article
- Learning and memory performance in a rat model of perigestational opioid exposure.Psychopharmacology · 2026Article
- Maternal control during prenatal oxycodone exposure: differential effects of voluntary versus involuntary self-administration on offspring substance use vulnerability in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- A comparison of dual vs. single diagnostic code approaches for neonatal opioid withdrawal syndrome surveillance in neonates ≥ 35 weeks gestational age.BMC pediatrics · 2026Observational
- Early pharmacotherapy versus no pharmacotherapy: difference in skin conductance response to physical stimuli in infants with neonatal opioid withdrawal syndrome.BMC pediatrics · 2026Observational
- PregMedNet: Multifaceted maternal medication impacts on neonatal complications.Nature communications · 2026Article
- Limbic System Microstructure in Neonates With Antenatal Opioid Exposure.JAMA network open · 2026Article
- Prenatal Substance Exposure and Birth Weight: Findings From the HEALthy Brain and Child Development Study.Pediatrics · 2026Observational
- Antenatal Opioid Exposure and Cerebral Cortical Maturation in Newborns.JAMA network open · 2026Article
- Substance use patterns among individuals who consume alcohol during pregnancy: Results from a US multi-site study.Drug and alcohol dependence · 2026Article
- Prospective observational study quantifying maternal-fetal fentanyl transmission in epidural analgesia infusion using umbilical cord blood and neonatal meconium.Journal of perinatology : official journal of the California Perinatal Association · 2026Observational
- Predictors of Opioid Misuse and Abuse Among Pregnant Women in the US.Pain management nursing : official journal of the American Society of Pain Management Nurses · 2026Article
- Hippocampal Development in a Rat Model of Perigestational Opioid Exposure.bioRxiv : the preprint server for biology · 2026Article
- Disrupted Brain Connectivity in Newborns Following Antenatal Opioid Exposure.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026Observational
- Fetal brain volumes and brain gyrification index associated with opioid exposure.Brain communications · 2026Article
- Article
- Anxiety, Depression, and Emotional Dysregulation Following Prenatal Substance Exposure.Advances in experimental medicine and biology · 2026Review
- Placental MRI texture features in prenatal exposure to opioids and tobacco.Scientific reports · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrescription opioid use during pregnancy has been associated with poor outcomes for mothers and infants. Studies using administrative data have estimated that 14%-22% of women filled a prescription for opioids during pregnancy; however, data on self-reported prescription opioid use during pregnancy are limited.
methodsCDC analyzed 2019 data from the Pregnancy Risk Assessment Monitoring System (PRAMS) survey in 32 jurisdictions and maternal and infant health surveys in two additional jurisdictions not participating in PRAMS to estimate self-reported prescription opioid pain reliever (prescription opioid) use during pregnancy overall and by maternal characteristics among women with a recent live birth. This study describes source of prescription opioids, reasons for use, want or need to cut down or stop use, and receipt of health care provider counseling on how use during pregnancy can affect an infant.
resultsAn estimated 6.6% of respondents reported prescription opioid use during pregnancy. Among these women, 21.2% reported misuse (a source other than a health care provider or a reason for use other than pain), 27.1% indicated wanting or needing to cut down or stop using, and 68.1% received counseling from a provider on how prescription opioid use during pregnancy could affect an infant. CONCLUSIONS AND IMPLICATIONS FOR PUBLIC HEALTH PRACTICE: Among respondents reporting opioid use during pregnancy, most indicated receiving prescription opioids from a health care provider and using for pain reasons; however, answers from one in five women indicated misuse. Improved screening for opioid misuse and treatment of opioid use disorder in pregnant patients might prevent adverse outcomes. Implementation of public health strategies (e.g., improving state prescription drug monitoring program use and enhancing provider training) can support delivery of evidence-based care for pregnant women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.